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“The Same Thing in a Different Box”: Similarity and Difference 
in Pharmaceutical Sex Hormone Consumption and Marketing _____________________________________________________________________________________________________	  
The contraceptive pill has given way to a multitude of products, packaging, and modes of 
administration. This article draws on work on the pharmaceutical copy, extending the 
analysis to differentiating between forms of administration for contraceptive medicines as 
well as between brand-name drugs, generics, and similares, as they are known in Brazil. It 
explores how Brazilian prescribers and users—within the divergent structural constraints 
afforded by private and public health—apprehend and negotiate distinctions between the 
drugs available to them. This ethnographic account of hormone use reveals new fault lines 
through which the pharmakon exerts it influence. The attention that industry places on 
pharmacodynamics as it produces new products from similar compounds suggests that 
pharmaceutical effects are at once symbolic and real. The article concludes with a reflection 
on the future of the generic form in a field increasingly crowded by branded copies. 
[contraception, pharmaceuticals, generics, the pill, Brazil] _____________________________________________________________________________________________________ 
 
Introduction  
 
The oral contraceptive pill has become a fairly ubiquitous object. So much so that it is known 
as the pill. Yet, behind the apparent unity of this object lies what Mol (2002) would call 
“multiplicity.” This article examines what gives this medical object its unity and analyzes the 
social and regulatory practices that are at work in the making or unmaking of this unity. My 
concern with how synthetic sex hormones are produced as contraceptives stems from an 
ethnographic conundrum. In studying the impact of the pill on women’s contraceptive 
practices, one is faced with an array of different objects, often lumped together as one. How 
can a thing like the pill be one and many simultaneously? Why does this object vary so 
widely? How can we account for its concurrent lability and condition as a tangible, material 
object?  
Since its inception in the early 1960s, the pill has given way to a multitude of products, 
in different forms of packaging and modes of administration. First, there is a profusion of 
orally administered pills: combination pills (estrogen and progesterone), mini-pills, extended-
regime pills, or emergency pills, combining any variation of the plethora of synthetically 
produced hormones. These can, in turn, be brand-name drugs produced by international 
pharmaceutical laboratories or copies of these. This article is based on ethnographic research 
in Brazil, where a dynamic pharmaceutical industry specializes in copying what are locally 
referred to as medicamentos de marca (brand-name medicines) (Cassier and Corrêa 2009). 
Only a small percentage of these copies are registered as “generics” by the Brazilian Agency 
of Sanitary Vigilance (ANVISA) in charge of pharmacovigilance. 
The majority of copies currently available in Brazil are classified as similares 
(literally, similar drugs)—not generics—and it is widely estimated that these represent 65% 
of the total Brazilian pharmaceutical market. In addition to this profusion of oral forms, 
contraceptive sex hormones may be injected, implanted subdermally, absorbed through the 
skin (via transdermal patches or gels), the vagina (via a vaginal ring) or the uterus (via an 
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intra-uterine hormone-releasing system). The making of this multiplicity relates to the search 
for long-acting contraceptive methods for the so-called developing world in which Brazilian 
medical institutions played a significant role.  
This article explores the dynamic between similarity and difference in pharmaceutical 
sex hormone marketing and prescription strategies in Brazil. This dynamic hinges on a 
process of multiplying different consumer populations within complex and shifting 
biopolitical rationalities of reproduction (Krause and De Zordo 2012; Sanabria 2010a). In the 
late 1980s, Brazil underwent a period of democratic reform in which the “universal” public 
health system known as the Sistema Único de Saúde (SUS) was consolidated. The SUS 
coexists with a dynamic system of private health to which 20–25% of the Brazilian 
population subscribes.1 Many private health institutions provide services for the SUS, 
sometimes offering a dual standard of care. 
Health disparities within Brazil are further compounded by important regional 
variations in access to services. Access to contraception in Brazil is highly stratified, 
revealing profound socioeconomic disparities, notably in its reliance on surgical sterilization. 
Although rates of sterilization declined from 38.5% of contraceptive use in 1996 to 25% in 
2006, significant disparities emerge when analyzing these figures according to level of 
education or economic class.2 Non-oral hormonal methods, such as contraceptive injections, 
hormonal implants, or intra-uterine hormonal devices like Mirena, are specifically pitched by 
health providers as alternatives to sterilization—the rates of which remain 
uncharacteristically high. 
Pharmacies remain the principle source for hormonal contraceptives, particularly for 
those groups at either end of the social spectrum. To understand the dynamics around 
hormonal contraception use, one therefore needs to look beyond the activities in the public 
health sector and to pay attention to the prescription practices in the private sector and to 
what take place across the counter, in pharmacies. This is a blind spot in much of the 
literature on contraception in Brazil, which, in focusing on women’s perceptions or the 
problem of unmet contraceptive needs, overlooks the way contraceptive decision-making is 
also shaped by feedbacks between pharmaceutical promotional strategies and prescription 
practices or by the dynamics of “switching” that take place within pharmacies.  
 
Methods and Setting: Tracking Pharmaceuticals in Salvador da Bahia  
 
The ethnographic materials presented here were gathered in Salvador, capital of the 
northeastern state of Bahia, as part of a research project on menstruation, contraception, and 
sexual and reproductive health practices. This involved 18 months of fieldwork (in 2005–6) 
during which I attended over 300 family-planning consultations across three distinct public 
sector services and in several private practices.3 I also conducted over 70 in-depth interviews 
with women across all classes. 
During this period and in four subsequent visits of three to six months between 2008 
and 2013, I attended three medical congresses and interviewed doctors, nurses, and health 
planners. The repackaging of hormonal contraceptives rapidly emerged as an important 
methodological concern, so I embarked on ethnographic work in the pharmaceutical sector. I 
carried out several weeks of fieldwork in three pharmacies catering to low-, middle-, and 
high-income neighborhoods and met pharmacy sector regulators and members of pharmacist 
professional organizations. I interviewed the national marketing directors of four major 
pharmaceutical corporations in São Paulo (Schering, Pfizer, Libbs, and Boehringer 
Ingelheim) and followed the work of Schering’s, Libbs’s, and Organon’s regional managers 
over the course of several months. I met a number of other pharmaceutical representatives in 
doctors’ waiting-rooms, some of whom allowed me to observe their work.4 Through these 
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contacts, I was invited to several pharmaceutical promotion events (such as conference 
dinners and congresses).  
 Although 90% of drugs are bought out of pocket (Thuot et al. 2012), Brazil is one of 
the largest consumers of pharmaceutical drugs and the seventh-largest market worldwide. A 
cardiologist cited by Petryna (2009:145) attributes Brazil’s “voracious pharmaceutical 
demand” to aggressive marketing, lack of enforced state regulation, and a bias for brand-
name drugs. Growth in the pharmaceutical sector is estimated at 13%, partly due to a 
booming industry of generic copies. This places Brazil among the high-growth nations 
referred to as “pharmerging.” Pharmerging markets are characterized by the Institute for 
Healthcare Informatics by a rapid increase in drug consumption, with a shift in spending 
away from branded products toward generics (IMS 2011). These shifts are imputed to a 
synchrony between historically high levels of patent expirations and improved economic 
conditions driving demand for drugs, particularly generics (IMS 2011:3). This points to 
tremendous tensions between brands and copies in global pharmaceutical markets. 
 The concept of pharmerging sheds light on how national development, 
democratization through the extension of citizenship to the global poor and pharmaceutical 
consumption are imbricated in conceptualizations of the role of pharmaceuticals in global 
development. In this article, I examine some implications the dynamics of pharmerging 
markets has on the way drugs are perceived and used in Brazil. I explore how Brazilian 
prescribers and users—within the divergent structural constraints afforded by private and 
public health—apprehend distinctions between brand-name contraceptives, their copies, and 
their different modes of administration. For this reason, I trace the differences among what is 
commonly presented as similar and the similarities that insinuate themselves in things 
presented as different. This attention to the interplay between similarity and difference takes 
its inspiration in the work of Hayden (2007, 2010) on the pharmaceutical copy, extending the 
analysis to the work of making difference and similarity between forms of administration for 
hormonal contraceptive methods. 
 
Interchangeability: How Different Things Are Made Similar 
 
Throughout the 1960–70s, and under the military dictatorship of Getúlio Vargas, the 
Brazilian state adopted an explicitly pronatalist stance. The absence of a national family-
planning strategy created a void. Corrêa (2001:56) argues that the “medicalization of 
reproduction” in Brazil was led by private sector initiatives, often contrary to the official state 
position. This resulted in a contraceptive praxis characterized by drugstore-promoted self-
medication that gradually leads women to turn to sterilization. Mapping the history of the 
pill’s uptake in Brazil is difficult because it was not introduced as part of a planned public 
policy (Loyola 2010; Pedro 2003). Enovid, the first pill to be introduced in Brazil, was 
promoted by salespersons in private gynecological practices and available in pharmacies, 
although its cost was prohibitive for most (Pedro 2003). The pill was unevenly diffused 
among low-income women by the interventions of international non-governmental 
organizations. The first state program to include family planning was launched in 1977. In 
her oral history of the pill in Brazil, Pedro (2003) found that women recollected experiencing 
many discomforts with the pill, a fact mirrored in the media coverage that emphasized, from 
the outset, the risks and side effects of the initially highly dosed pills.  
Contraceptive choice is a foundational aspect of reproductive and sexual rights. 
Hartman (1995) argues that population control programs impose birth control from above, 
limiting choice of methods. Against this, she pitches reproductive health programs that offer 
a wide range of methods and access to safe abortion (Hartman 1995:57). The distinction is 
more heuristic than descriptive, as elements of both ideal types exist in the day-to-day 
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practices of reproductive health services worldwide. However, it illustrates the rhetorical 
importance of contraceptive method diversity in reproductive health. My aim is to highlight 
the ways in which this contributes to constructing a form of interchangeability between 
contraceptive methods and between hormonal methods in particular. This permutability 
between methods opens up the first notion of similarity between medicines that I would like 
to highlight. The logic of choice that permeates these contexts implies that women select 
from a range of similar options. In the context of promoting choice, differences between 
methods are temporarily bracketed, as an emphasis is placed on finding the most suitable 
method among what is essentially foregrounded as equivalent choices.  
In Bahian public ambulatórios (out-patient clinics), it is common for choice to be 
limited by a lack of methods. The methods available in the family-planning units I researched 
tended to include one or two types of oral contraceptive pills, hormonal injections, and 
copper intra-uterine devices. In these contexts, where the average consultation with the 
doctor is seldom longer than five minutes, women who express difficulties with a particular 
pill or want to change methods are given whatever else is available. Public ambulatórios 
generally administer pills by packs of three, and pill users often return to find that the pill 
they have been using is no longer available. This renders whatever else is available 
interchangeable, by default, inverting the logic of choice into a logic of necessity, of sorts. In 
these public services, teenage girls are often proposed the injection in place of the pill, when 
it is available. One doctor I interviewed justified this as follows: “The injectable is much 
more effective. […] That way, we know for sure the patient won’t get pregnant and that we 
are not wasting resources.” 
Injectable contraceptives are pitched as a reliable alternative to the pill for young 
women, who are considered esquecidas (forgetful). In Salvador, much attention is given to 
the risky sexual practices of teenage girls leading to unwanted pregnancy (see Marinho et al. 
2009). Although injections are barely represented in the available 2006 population-wide data 
on contraceptive use (Perpétuo and Wong 2009), I found that this was often the second or 
third most-delivered method in the public health posts in which I carried out observations.5  
Oudshoorn’s (1996, 1997) historical work on hormonal contraception provides a 
context to understand the dynamic of interchangeability that I am foregrounding here. She 
traces the gradual demise of the “One Size Fits All” approach to contraception promoted by 
early developers of the pill (Oudshoorn 1996). This led to the development of a “cafeteria-
model” of hormonal contraceptive diversity.6 In the late 1970s, the WHO actively promoted 
research on long-acting hormonal contraceptives (hormonal injections and implants, in 
particular). These were seen as efficacious tools for population control programs because 
they are provider administered. This makes them good “technical delegates,” that is, artifacts 
that are “designed to compensate for the perceived deficiencies of [their] users,” such as 
women’s tendencies to forget to take their pills daily (Oudshoorn 1997:44). 
The WHO R&D program stemmed from the recognition that “the” pill had only been 
taken up by “middle- and upper-class women in the western industrialized world” and not by 
women “in Southern countries” (Oudshoorn 1997:43). Injectable contraceptives such as 
Depo-Provera are described by the WHO team in a Science publication as “appropriate in 
developing countries but of relatively little interest in highly developed ones” (Crabbé et al. 
1980).7 Technologies such as the pill contain a configured user (Oudshoorn 1996) that can 
inhibit its capacity to enter into new sociopolitical contexts. 
For the pill to travel, it needed to be unpacked. Its circulation depended on making the 
object more fluid, so to speak (de Laet and Mol 2000). As new objects were produced from 
sex hormones, their circulation worked to differentiate between different consumer 
populations. This background is important for understanding how choices are presented in 
public family-planning institutions in Bahia. Low-income patients tend to be perceived as 
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ignorant or inconsistent, and, although birth rates have decreased significantly in Brazil, 
relations between unbridled fertility, underdevelopment, and poverty continue to be 
commonly drawn in popular imaginaries. 
Just as the pill and the injection are often rendered interchangeable, pills are readily 
swapped for each other. The work of choosing from the huge array of available pills is an 
exercise in differentiating between similar things. This work is heavily influenced by the 
active work of pharmaceutical representatives who strive to differentiate their products. One 
morning I sat with a gynecologist in a maternity unit in a small town near Salvador where 
private and public consultations were held back to back, in the same space. A young woman 
came in from the list of public-service patients. She discussed contraceptive options with the 
doctor, showing herself to be knowledgeable of different hormones and using the space to air 
queries about side effects. Although the young woman was not a paying patient, it was clear 
she did not want to be administered the standard pill available in the health post. She asked 
about the vaginal ring that she had heard about from her cousin and about the difference 
between the mini-pill and Ciclo21 (a popular Brazilian copy of Schering’s Microvlar). They 
discussed Yasmin, “an excellent option,” the doctor declared, but “very expensive.” They 
settled on Levell and the doctor advised: “See how you get on with this. Take it every day at 
the same hour. And we’ll explore until we find the right one for you.” 
The production of difference in such contexts is attendant on a prior notion of 
similarity that makes interchangeability possible. This notion of similarity is essentially 
analytical. Part of the ambiguity arises from the way contraceptive methods are classified. 
Most classifications blur use and mode of action. Contraceptive methods can be “barrier,” 
“behavioral,” “permanent,” “emergency,” or “long-acting reversible,” and Brazilian 
categories until recently distinguished between “modern” and “traditional” methods. Popular 
categories tend to group methods according to their mode of administration rather than mode 
of action (thus differentiating between oral, injectable, or intra-uterine methods, across which 
hormonal methods are spread). While not everything is constructed as the same thing, and 
differences are produced between methods, my point is that the logic of interchangeability 
functions to smooth out differences between methods in the context of producing 
contraceptive choice. In the following section, I examine how ostensibly similar medicines 
may nevertheless be treated as radically different things, revealing how strategic the 
suspension of differences or the emphasis on similarity and interchangeability can be.  
 
Small Gaps, Big Differences  
 
Historian Watkins (2012) argues that there is nothing innovative about the purportedly new 
hormonal methods currently available on the market. Their sole novelty, she argues, resides 
in the marketing of the secondary, or lifestyle, effects of sex hormones. Watkins traces the 
tactics for “tinkering” with the pill’s design, arguing that pharmaceutical companies 
promoted “distinctive aspects of what were essentially similar products” (2012:1465). The 
introduction of slight variation supplants genuine innovation with mere imitation (Watkins 
2012:1465). 
Interestingly, Watkins dwells less on the development of new modes of administration, 
concluding that the contraceptive options available to women today hardly differ from those 
available to their grandmothers (Watkins 2012:1464). This reveals how Watkins constructs 
the notion of similarity. Her notion of “hardly different” hinges on the similarity of the active 
principles themselves. She shows the extent to which sex hormone marketing hinges on 
demonstrating differences within non-contraceptive properties of “new” products. However, 
her analysis risks overlooking the way in which, in practice, marketing produces very 
different things. Small innovations produce big differences for users and prescribers alike. 
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There is perhaps nothing new to the levonorgestrel compounds used in Norplant implants, the 
Mirena intra-uterine hormone-releasing system, or emergency contraceptive Plan B. However, 
these are so different in the minds of the women, doctors, and pharmacists I interviewed that 
they do not even enter a common category.  
Yolanda is a tall, enthusiastic woman in her late twenties. We met one day in the 
waiting room of a private clinic, where a gynaecologist was running two hours late. Yolanda 
wears the characteristic smart office garb of pharmaceutical representatives and has a black 
attaché case full, I imagine, of amostras (free samples). She is a pharmaceutical 
representative for Nuvaring and is zealous about this “completely novel approach” to 
contraception. Nuvaring is a small silicon ring inserted in the vagina once a month. Yolanda 
explains to me that private practice doctors are enthusiastic about Nuvaring but have come up 
against “taboos” in prescribing this method. 
Yolanda pulls a three-dimensional plastic model of the female reproductive organs out 
of her attaché case, explaining that she gives one to each doctor so they can educate their 
patients about the vagina, showing them how and where to insert Nuvaring. “Although we 
live in a very sexualized culture here in Brazil,” she explains, “women don’t know their own 
anatomy and have very traditional ideas still.” Organon-Brasil actively works on this sexual 
trope in its marketing strategies. Yolanda enthusiastically recounts an event she recently held 
in a sex-shop for a group of female gynecologists. The objective, she explains, is for the 
gynecologist to become a purveyor of information about pleasure and sexuality and to have 
access to new ideas and information in this respect.8 The doctors she visits feel that their 
patients are not ready for this new approach to contraception. As one female gynecologist I 
interviewed explained:  
 
Nuvaring is such a lovely method. But women have all sorts of preconceptions about 
it. That they will lose it in their vagina, or that their husbands will feel it. You have to 
explain that the vagina is a closed cavity, that Nuvaring can’t be felt, and then you 
still have to get them to overcome their hang-ups about putting their hand in their 
vagina.  
 
In the process of expanding contraceptive choices to patients, Nuvaring appears as 
something radically different for caregivers. This dispenser mechanism may have been 
experimented with for over 40 years and contain entirely un-innovative steroid compounds, 
but as it is taken up by users, this object arises as a markedly different thing. The logistics of 
its use (inserted for three weeks, removed, and then reinserted one week later) and the locale 
of application (the vagina) contribute to rendering the similar aspects (to the pill) almost 
negligible. Depending on the perspective adopted, this object appears as either just the same 
old thing in new garb (Watkins 2012) or as radically different. These differences may seem 
so considerable to end users that it causes them to lose sight altogether of the fact that they 
are using a hormonal contraceptive method. Many of the women who use the hormone-
releasing Mirena intra-uterine device or hormonal implants opt for these methods precisely 
because they do not like the pill. While hormonal injections remain closely associated to and 
interchangeable with the pill, Mirena and implants have come to be perceived, by users, as 
unrelated to the pill. 
Nara runs a small business and has been using Mirena for two years. She is 29 and has 
a four-year-old daughter who lives with her and her parents in a modern high-rise building. 
As a busy working mother, Nara appreciates not having to think about contraception daily. 
Her contraceptive history is marked by what she calls an “erratic” use of the pill. Her 
pregnancy was unplanned and, after an abortion three years later, she used a copper IUD. 
This gave her painful and heavy periods, and she became aware of having what she describes 
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as “tremendous” premenstrual tension. Her gynecologist suggested Mirena—which is often 
prescribed in such cases—and her partner helped her meet the cost, which amounted to over 
US$250. Nara explains that she never “got on” well with hormones, although Mirena has a 
hormonal delivery system and that she enjoys the fact that Mirena suppresses her period. 
When I press her on this she laughs, stating: “It’s totally different.” This can be explained by 
the fact that Nara adopted Mirena specifically as an alternative to the pill: “I went for it as an 
anticoncepcional (contraceptive), to be free to travel and everything without having to 
depend on a pill. And I got on well with it. And on top of everything, I stopped menstruating, 
then I was really loving it. I recommend it to everyone.”  
Likewise, Simone has been using hormonal implants for six years because she dislikes 
the pill. She is a professional photographer and runs a large events business. We met through 
mutual friends, and she and her husband, Carlos Eduardo (Cadu), humorously agreed to an 
interview because they were “in the middle of a family-planning crisis,” debating whether or 
not to have a third child. Their first child was conceived while Simone was using the IUD, 
less than a year into their relationship. Simone adopted the implant after their second child 
because of its contraceptive reliability. Cadu—they both joked one evening over dinner—
loved the implants because, they agreed, Simone was “infernal” when she menstruated. 
Simone who is vegan, a yogi, and makes use of a range of holistic therapies, such as Reiki, 
explains that she never uses medications and prefers to heal herself through meditation or by 
attending to the meaning that a particular physical ailment is conveying. She speaks of loving 
her implants in terms of a “confession,” explaining that they give her tremendous 
“disposition” for life but that she worries “about what it might be doing to my organism. I 
love it, but I’m scared of using another one.” 
Simone recognizes the hormonal composition of her implants and its risks, and 
appreciates the effects of the testosterone that heightens her tesão (sexual desire) and gives 
her extra physical strength, but she clearly differentiates the implant from the pill—which she 
notes is more highly dosed—or the morning after pill that she describes as a “hormonal 
bomb.” Beyond its practicality as a contraceptive, this method appears to Simone as less of a 
biomedical intervention in that she does not have to take a pill every day, a fact that sits more 
easily with her holistic vision of health. However, it enables her to sustain her demanding 
lifestyle and meet her professional and social obligations unencumbered by what she calls 
“emotional disruptions” or “menstrual fraqueza (weakness).”  
How to account for the fact that so many hormonal implant and Mirena users I 
interviewed explicitly rejected any association between these and the pill?9 Modifications in 
the mode of administration induce changes in the perception and experience brought about by 
the object that may be so significant that they eclipse the common hormonal action between 
two drugs. To some extent, biomedical technologies such as Mirena or hormonal implants 
cease to appear as drugs, despite their pharmacological action. Marketing for Mirena 
somewhat downplays its hormonal action, drawing attention to the fact that it is an intra-
uterine device. It is therefore understandable that this method is less associated with its 
hormonal action. However, hormonal implants are widely appreciated for their menstrual 
suppressive action, and much of the promotion made of this method centers on controlling 
the hormonal fluxes associated with premenstrual tension. The implants are marketed as 
making possible a kind of hormonal enhancement that, according to some gynecologists,  
enables a form of sexual enhancement captured by the idiom of having disposição 
(disposition) by adducing exogenous testosterone or estrogen.10 
Beyond facilitating use and overcoming forgetfulness, non-oral sex hormone 
repackaging strategies bear directly on the bioavailability of an active principle in the body. 
When a drug is swallowed and absorbed by the digestive system, it is metabolized by the 
liver. This reduces the bioavailability of the drug, requiring the administration of a higher 
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dose. Alternative routes of administration avoid so-called first-pass effects through their 
delivery directly into the circulatory system. Differences of these kinds have important 
ramifications on the way an otherwise similar chemical compound acts in the body. Users’ 
subjective experiences of a drug’s efficacy are thus mediated by a range of factors that 
include its active principle, its mode of administration—which, in turn, determines the drug’s 
pharmacokinetics—and the symbolic and social context within which it is prescribed and 
consumed. 
Recent work in pharmaceutical anthropology (e.g., Schlosser and Ninnemann 2012) 
calls for the need to understand pharmaceutical efficacy in relation to the biological, 
sociological, and structural factors that shape individual responses to drugs. The cases 
discussed here reveal new fault lines through which the pharmakon  exerts its influence, 
collapsing the distinctions between biological and sociological factors. The attention the 
industry places on pharmacodynamics suggests ways in which effects are both biological and 
social, symbolic and experienced in the flesh. In repeatedly alluding to differences in the 
effects of non-oral methods, these women are speaking at one and the same time of 
differences in the rates and magnitudes of pharmacologic responses, in the quotidian 
practices of use and in the medical encounters where these method are prescribed—as well as 
ensuing differences in the subjective identities locally conferred by “having an implant” or 
“using Mirena.” 
These cases reveal how different the same thing, repackaged, can look and feel. They 
point to what can be gained by considering pharmaceutical efficacy as the cumulative effect 
of the reputation, appearance, or subjective attachments to specific drugs, to their brands, 
pharmaceutical formulations, and modes of administration as well as to the social contexts 
within which drugs are used. The production of difference or the demonstration of similarity 
hinges on the enrollment of an intricate meshing of chemical, structural, economic, and 
semiotic elements. In this sense, the pharmaceutical effects I am underscoring here are prime 
examples of what Haraway (1991:200) calls “material-semiotic” nodes. 
 
Pharmaceutical Copies and Substitutions: Differentiating the Similar  
 
Given that roughly 75% of all hormonal contraceptives are obtained directly in pharmacies, 
often without prescription, these became privileged ethnographic sites.11 My observations in 
Bahian pharmacies allowed me to witness the practices of pharmaceutical substitution that 
commonly take place over the counter. Typically, clients arrive requesting a specific drug 
they have been prescribed or recommended or that they have failed to obtain in their local 
health post. It is common for the balconista (shop vendor) to answer that the drug is 
unavailable and add: “But we have the similar. It’s the same thing.” If the client is hesitant, 
the balconista may call attention to the similarity in the composition of the drug being offered, 
adding “and it’s cheaper.” 
Similares often cost a fraction of the price of brand-name drugs. When clients inquire 
as to the significant price difference, balconistas may explain this by saying that brand-name 
drugs are imported while similares are “national products.” Brand-name drugs have a certain 
prestige to them, like other imported goods. Imported goods such as grifes (designer goods), 
cosmetics, electro-domestic appliances, or electronics bring with them the social attributes of 
the elites who have access to them, so consuming them becomes a means of accessing elite 
status (Yaccoub 2011). Differences between imported brand-name drugs and similares are 
often presented by balconistas as one of packaging or origin, while the likeness between 
active principles is emphasized. Similares are usually promoted directly to pharmacies rather 
than to doctors. Several informants estimated that balconistas earn commissions of up to 50% 
on each box of similares they sell. This practice encourages balconistas to substitute brand-
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name medicines with similares. Given that Brazilians buy drugs out of pocket, the similar 
marketing strategy is extremely efficient and explains why more than half of drugs sold in 
Brazil are estimated to be similares. This has become a major sticking point, particularly as 
few pharmacies operate with a trained pharmacist. Although this was formerly illegal, 
pharmacy owners prefer paying fines to paying full-time pharmacists. In practice, in Bahia, 
pharmacists often “rent” their names to a pharmacy while working full-time jobs in 
laboratories (Kamat and Nichter [1998] relate a similar situation in India). 
Despite recent efforts to levy fines more regularly, it is still rare to find a pharmacist 
behind the counter in Salvador. This is often seen as facilitating self-medication.12 During an 
interview, the president of Bahia’s Pharmacy Council joked: “Even my own mother se 
receita (prescribes herself) and receita others in the family, so what can we do?” Almost 
anything is available without prescription in pharmacies (despite clear indications to the 
contrary on prescription drug packages), facilitating prescriptive forms of sociability, where 
people exchange information informally about the medicinal regimens they obtain directly, 
and often without prescription, in pharmacies.  
 Schering’s regional representative, Anderson, a jovial and seductive father of two in 
his mid-thirties took me out on several occasions “to visit his gynecologists.” The private 
practices in Anderson’s clientele are luxurious, their interior design mixing white marble 
floors, spotless glass doors and colorful popular art. Each consultório has its own “look,” and 
the predominantly female doctors wear pastel-colored lab coats with their first names 
embroidered in bright colors. Schering’s products are considered muito chique (very chic), as 
one gynecologist put it. 
On one occasion, Anderson and I ran into a group of representatives, identifiable by 
their matching black attaché cases. Vinicius, a representative from a Brazilian laboratory, 
approached me while Anderson was talking loudly on his flashy cell phone to ask me if I’m a 
rep too. He seems new to the scene and full of zeal. Anderson has snubbed him, but Vinicius 
tells me: “He’s one of the best, his sales figures are unmatchable.” When the gynecologist 
calls the reps in, we go in together, to save her time. Vinicius begins, nervous, mechanically 
reciting his pitch and laying down a large batch of amostras that the gynecologist silently 
slips into a drawer in her desk. “This guy is just a distribuidor de caixinhas (a pill pack 
distributor),” Anderson whispers to me, “his lab pushes quantity over quality of encounters.” 
When it is his turn, Anderson engages in conversation with the doctor as an equal, taking his 
time, making a few jokes. He knows his products matter here. The doctor is more patient with 
him, his goods holding greater appeal. When the other reps have slipped out, thanking the 
doctor for her time, Anderson launches into his pitch for Yasmin. He is concerned because 
Libbs, a Brazilian similar laboratory, is launching a copy of Yasmin called Elaní.  
 
Doctora, I want you to help me make Yasmin the number one option for your patients. 
It’s the best product on the market: It’s about your patient’s well-being. She won’t 
experience that swelling that makes her swap. And Yasmin is the real thing, the 
guarantee of quality, not just a copy.  
 
Anderson exposes his scheme of exchanging Yasmin samples for receipts that ensures 
patients effectively get two boxes for the price of one and that he obtains a sale of Yasmin 
instead of seeing it swapped in the pharmacy for the similar.13 The doctor accepts, requesting 
a sample of the contraceptive injection Mesygyna for her empregada (domestic employee) 
who has just had an abortion. “I just can’t do without her,” she explains as she places the 
injection in her designer handbag. Doctors often pass on the free samples they receive to their 
kin or staff, a practice that pharmaceutical reps attempt to minimize to ensure each sample 
they deliver results in a sale. Anderson explains when we leave the consultório that 
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laboratories source data from tertiary organizations to generate a sales potential indicator for 
each doctor he delivers amostras to. He jokes that as the market saturates his job has become 
that of a “sniper” as he has only one shot (or sample) to hit his sales target. For this reason, he 
is concerned about the substitutions that take place in pharmacies, undermining his 
painstaking work.  
The substitution of reference drugs with similares is also common in public health 
services. When women express reluctance regarding the swapping of a pill for a different 
brand, doctors also employ the idiom of similarity to encourage skeptical patients to accept 
the proposed drug. Emphasis might be placed, as in the pharmacy, on the similitude of active 
principles and differences presented as merely ones of packaging or origin. What is 
interesting is that substitutions between reference drugs and their copies can work in both 
directions, so to speak, such as when the copy becomes a popular reference in itself. This is 
the case with the contraceptive pill Ciclo21, the Brazilian copy of Schering’s Microvlar. It 
was revealed through an exchange I witnessed in an ambulatório on Salvador’s periphery. 
The only pill available there was Microvlar, a pill that was the subject of a national 
scandal after some 50 women declared that they had become pregnant while using it. A 
woman entered the consultation room and requested the renewal of her Ciclo21 prescription. 
The doctor took out three boxes of Microvlar, mechanically completing her file. The patient 
protested, asking why he was changing her pill. The doctor replied that they had not received 
Ciclo21. “However,” he affirmed, “Microvlar is exactly the same thing, in a different box.” 
Doubtful, the patient crossed her arms and said she did not get on well with Microvlar. 
Irritated, the doctor reiterated: “The only thing that’s different is the box, querida (darling)! 
Are you going to eat the box, too?” Unflustered, the woman answered that she would prefer a 
prescription for Ciclo21. Attempting a more conciliatory tone, the doctor began reading out 
the “ingredients” on the box. “It’s a shame, when you can get the exact same thing here for 
free,” he lamented. Legally, similares—which are not considered interchangeable with 
reference drugs—should not be available in the SUS. However, the supply of drugs in the 
public sector obeys a law of bids (Lei de Licitações), which favors the laboratories that offer 
the lowest prices, generally similares.  
These cases reveal some of the issues at play around the circulation of copies in the 
Brazilian pharmaceutical landscape. The market for copies has a complex internal dynamic, 
both where the difference between copy and original is concerned and between copies, which 
I now turn to. The substitution of brand-name drugs with similares or generics has unleashed 
a complex chain of regulatory practices around the copy. In Brazil, like elsewhere, the 
proliferation in types of copies arises out of questions concerning the quality of copies. As 
Hayden (2010:2) has argued, “the field of ‘the copy’ […] is crowded.” In attending to the 
conceptual work that similarity does as it is transformed into a proper noun, Hayden opens up 
important questions about the differences that matter in claims to similarity. 
Branding, in the field of the pharmaceutical copy, consists not in carving distinctions 
out of a field of equivalent products (Coombe 1998) but—to the contrary—in making 
likeness a mark of distinction (Hayden 2013). In the Mexican case that Hayden relates, 
similares are not a regulatory category but a successful brand of pharmacy that sells generic 
drugs. In Brazil, similares form a regulatory category and refer to copies that are equivalent 
to a reference drug in their chemical make-up (i.e., composed of the same active principles in 
equivalent concentration). They are, however, differentiated from generic drugs that are 
considered more equivalent and thereby “interchangeable” with a reference drug. 
The category “generic” arose relatively late in Brazil and it was only in 1999, with the 
creation of ANVISA, that the distinction between similares and genericos was consolidated 
in regulatory terms. This distinction centers on the demonstration of both chemical 
equivalence and bioequivalence, that is, in terms of how the drug is metabolized by the body. 
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Hayden refers to this distinction as one between pharmaceutical as effect rather than as 
substance (Hayden 2010:6). In practice, proving bioequivalence requires the realization of in 
vivo tests to measure how a copied compound acts in a living human body. Given that 
bioequivalence is a statistical measure that allows a variation of 20% between the 
bioavailability of a reference drug and its copy, the gold standard of quality—
bioequivalence—effectively “means same enough” (Hayden 2010:7; emphasis in the 
original).14  
Mauro, a consultant for a regional pharmacy chain who introduced me to several 
pharmacies, explained that brand-name drugs are promoted by representatives in doctors’ 
practices, and similares are promoted in pharmacies, but that “nobody promotes generics, 
they’re stuck on the pharmacy shelf, not actively represented.” He works with a view of 
democratizing access to drugs and redeveloping the role of pharmacists beyond the “merely 
mercantile.” As a public health–minded pharmacist and a member of the social movement, he 
downplays the difference between “researched” brand-name drugs and their copies, referring 
to the quality of nationally produced drugs in nationalist-inflected tones. Such ideas date back 
to the 1930s, when Vargas—Brazil’s populist dictator and promoter of import substitution 
industrialization—declared that it was unpatriotic to use imported goods. By 1939, Brazilian 
pharmaceutical firms had integrated this into their marketing, drawing on the image of the 
“patriotic doctor” who prescribes national products that can “compete with and exceed 
foreign medicines” (Stücker and Cytrynowicz 2007). Mauro sees ANVISA’s request to 
submit all copies to bioequivalence testing with a favorable eye, as this will reinforce the 
credibility of Brazilian firms.  
ANVISA established in 2004 that all similar drugs must present tests to establish their 
bioequivalence with reference drugs to be (re)registered with the agency. The Brazilian 
pharmaceutical industry negotiated a 10-year interval to meet these requirements, which ends 
in 2014. Given the vast portion of the market occupied by similares, a revolution seems 
underway.15 What will happen to similares post-2014? Will they become generics or 
disappear? According to the Brazilian Law of Generics, a pharmacist can only substitute a 
brand-name drug with a generic. This raises an important question: If similares are submitted 
to the same tests as generics, will they become interchangeable with brand-name drugs? This 
is a grey area, as technically they will be, but legally it will not be possible unless the Law of 
Generics is modified. The main sticking point is the question of brand. 
To be interchangeable, similares would need to be generics, and to be generics they 
would need to lose their brand, as generics are identified by their active principles and not by 
their name, unlike similares. Is this, Portilho (2012) asks, the end of the brand for similares? 
It appears that ANVISA will not legislate on this issue, leaving it as a strategic decision for 
each business to make. The brands of which generics are stripped produce relationships 
between consumers and commodities (Manning 2010; Nakassis 2013). Their trademarks are 
loaded with sociocultural meaning. Without active promotion or clear channels of consumer 
identification, generics are somewhat forsaken, as Mauro notes. Relationships between 
branded products and their consumers are the product of extensive efforts to build trust and 
consumer identification with products. as illustrated by the case of Microvlar’s demise and 
Ciclo21 success.  
The Brazilian laboratory EMS Sigma Farma’s strategy is telling in this regard. In 
2012, it launched a generic version of the oral contraceptive pill Yasmin, containing the 
fourth-generation hormone drospirenone. Yasmin is one of Brazil’s leading brands, and is 
widely promoted for promoting bem-estar (well-being) by reducing swelling and weight gain 
due to the diuretic effects of the hormone drospirenone. Significantly, EMS simultaneously 
launched a new drospirenone-containing similar marketed as Dalyne, which is presented as a 
strategic competitor to Libbs’s Elaní (introduced above), itself a copy of Yasmin. Is 
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Dalyne—pharmaceutically speaking—the same as EMS’s generic copy of Yasmin, but with a 
brand? EMS is capitalizing on the bioequivalence testing to produce both generics and a new 
form of copy: a branded bioequivalent copy. This indicates that ANVISA’s call for all copies 
to be submitted to bioequivalence testing will not simply transform similares into generics. 
According to EMS (2013), Libbs currently holds half of the highly lucrative market for 
drospienone-ethinylestradiol contraceptives. EMS’s strategy aims to capture Bayer’s Yasmin 
clientele through legal substitutions by generics while encroaching on Libbs’s market with 
the promotion of the branded version of its bioequivalent Yasmin copy Dalyne (which is 
cheaper than its generic Yasmin). EMS’s market strategy is reflected in Dalyne’s branding 
which promises more: “More beauty, more lightness and more freedom for more women.”  
What is striking about this case is that drospirenone is still—according to Bayer—
under patent. In 2005, Libbs registered Elaní with ANVISA and was sued immediately by 
Schering (which has since been bought out by Bayer) for patent infringement. Libbs attacked 
on several fronts: It claimed that Schering’s drospirenone patent number 1101055-0 relies on 
technology described in patent DE 3.022.337, registered in 1980 and is therefore in the public 
domain. After two Brazilian rulings denied Libbs’s request to suspend Schering’s patent, 
Libbs took the issue to the Brazilian Supreme Tribunal of Justice and to this day, Schering’s 
patent has not been annulled, nor has Libbs been formally allowed or legally impeded from 
commercializing Elaní. 
I attended a series of launch events for Elaní in Salvador and discussed the case with 
Arnaldo, Libbs’s regional manager. He was confident that Elaní would go on the market as, 
in his words, it was more than just a copy. Unlike Yasmin, Elaní is marketed as an extended-
regime pill, designed to reduce the annual number of periods, and sold in packs of 28 pills. 
According to Arnaldo, Libbs would win against Schering as “Elaní is not just a copy, it 
innovates too.” These pharmaceutical maneuvers reveal the extent to which the market of the 
copy is subject to a process of segmentation. As the monopoly of brand-name drugs declines, 
lines of differentiation are drawn around the proliferation of emergent copies. The Brazilian 
pharmaceutical market is on the brink of a small revolution as similares are faded out and 
replaced by generics and a new pharmaceutical genre of branded bioequivalent copies. While 
EMS multiplies the sales opportunities for its bioequivalent Yasmin copies, Libbs’s strategy 
is a form of imitative innovation that effectively repackages the copy. These strategies reveal 
the extent to which pharmaceutical marketing carefully negotiates the line between the 
production of something genuinely different (to protect intellectual property rights) and 
something completely identical—or, at the very least, bioequivalent. 
 
Conclusion 
 
Pharmaceutical sex hormones are peculiar objects. As chemical compounds that can be 
administered to prevent ovulation, suspend menstruation, “treat” menopause, certain cancers 
or premenstrual stress, improve skin condition, or assist in sex changes, they have far-
reaching implications for definitions of gender, familial relations, well-being, and national 
demographics. In giving an ethnographic account of hormonal contraceptive use and 
prescription practices in Brazil, this article examines how the control of variation is 
strategically employed by the pharmaceutical industry. This thick description of the dynamics 
at play in pharmaceutical development, marketing, and procurement highlights the ways in 
which these shape and respond to consumer choices across Brazil’s two-tiered health system.  
 Given that the vast majority of hormonal drugs are procured directly in pharmacies, 
often without prescription, focusing solely on doctor–patient interactions in public services 
misses an important part of the picture. My aim has been to contribute to anthropological 
debates on pharmaceutical cultures as they relate to how drugs are made efficacious and to 
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tensions surrounding the pharmaceutical copy (Greene 2011; Hayden 2007, 2010, 2013; 
Whyte et al. 2002). 
 The article considers how diversity is produced from ostensibly similar things through 
an analysis of the emergence of non-oral modes of administration for sex hormones. 
Differences between contraceptive medicines are at times strategically suspended by health 
practitioners in the context of emphasizing method interchangeability. In family-planning 
consultations where differences between pills or between pills and injectables are often 
bracketed together, patients may reasons resist this bracketing, as we saw with the case of the 
woman who contested the prescription of Microvlar, preferring Ciclo21. Conversely, 
differences between oral contraceptives and the sex hormones repacked in new delivery 
mechanisms may be highlighted, effacing the common hormonal mode of action between 
them. This accounts for Nara’s statement that she does not do well with hormones, although 
she enjoys Mirena’s menstrual suppressive effects. It also accounts for how Simone can opt 
for hormonal implants while explaining that she does not use medication and prefers to 
meditate or attend holistically to her health.  
 Regarding the production of copied drugs, the pharmaceutical industry carefully 
works to limit variation, striving to replicate an equivalent copy through reverse engineering. 
My focus here has thus been on the interplay between two types of differences: between 
modes of administration and between brand-name drugs and their copies. Although these 
usually belong to different conversations, I examine them together to reveal the combined 
effects of modulations in dosages, “original” and “copied” active principles, modes of 
administration, and branding, which together produce the pharmaceutical efficacies that 
doctors, patients, and pharmacists navigate.  
 The specificity of steroid hormones, in relation to other pharmaceutical classes, is that 
users acquire them in a multitude of different galenic formulations, packaging, color, or name, 
each prescribed with slightly different indications or marketed to different patient profiles. 
Such variations, I have argued, have far reaching implications for the way in which the object 
is perceived, experienced and understood to be efficacious. “How can pills with similar 
contents look so different and pills with different contents look so similar?” Greene 
(2011:120) asks. “The brand of a drug does not stop at the name or logo. Rather, the brand 
extends into the pill itself, in the form of its particular contour, bevel, engraving, or colour” 
(Greene 2011:120). 
 Much of the existing work on the pharmaceutical copy has attended to intellectual 
property issues concerning the active principles and much less to how modes of 
administration or the materializations of brand that Greene outlines combine with these—a 
gap I attempt to fill here. The way hormonal contraceptives are experienced depends on a 
subtle balance of tangible and intangible elements that include, beyond the chemical 
composition of a drug, its design, name and, increasingly, its trademarked concept (e.g., 
FewerPeriods. MorePossibilities.™ for the Seasonale extended-regime pill). The concept that 
a brand carries, such as “well-being” or “weight-loss” that marketing has associated with 
Yasmin in Brazil, seeps into the hormonal substance itself, drospirenone, in this case. Thus, 
aspects of the branding process may percolate unevenly to the copies of the chemical 
compounds as these are remade by generic or similar laboratories.  
 The generic stands at the antipode of branding processes. So much so that trademarks 
are at risk of a cruel form of irony if they are too successful and turn into nouns or verbs, a 
process known as genericide. Legal regimes strive to separate trademarks and brands from 
the product, as when the brand and the thing merge the specificity of the brand is lost in the 
generic form. Pharmaceutical maneuvers around the generic must navigate a fine line, 
retaining something of the identity of the original, which, as we have seen, goes beyond its 
pharmacological composition. The immanent reclassification of similares in Brazil as either 
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certified generics or branded bioequivalent copies signals that generic drugs are gaining new 
competitors on the side of the copy. What difference does the oxymoron “branded-generic” 
make to the field the generic? Is this the “defeat of the generic revolution”—and its promise 
of delivering cheap and effective drugs to all—as one public health-minded pharmacist I met 
would have it?  
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1. Although this percentage has remained stable, the population has expanded from 70 
million in 1960 to 191 million in 2008. 
2. In 2006, 20.5% of women with at least eight years of schooling relied on sterilization, 
compared to 65.5% of women with no formal education (Perpétuo & Wong 2009:93–94). 
3. The doctors who allowed me to observe consultations usually engaged with me as well as 
with the medical students who were often present.  
4. My interest in the question of pharmaceutical copies brought forth extensive descriptions 
of the market dynamics at stake, from the perspective of those promoting them.  
5. This is supported by Perpétuo and Wong’s analysis, who state: “For women without any 
formal education, injectable contraceptives were the second choice, a little above female 
sterilization” (2009:100, my translation). 
6. It found its rationale in the limited uptake of the pill worldwide a fact accounted for by 
reference to the heterogeneity of women’s personal, cultural, and religious circumstances.  
7. Depo-Provera has a troubling history, worldwide. In the United States, it was repeatedly 
denied FDA approval until 1992. Women’s health organizations worldwide have opposed 
Depo-Provera, highlighting its potential for abuse and adverse health effects. 
8. In his ethnography of pharmaceutical sales practices, former-salesperson-turned-
anthropologist Oldani (2004) remarks on the importance of strategic gifting in 
pharmaceutical marketing. This gift economy, into which pharmaceutical corporations invest 
billions of dollars, serves to craft relations with doctors and gage promotional strategies as 
well as generate sales.  
9. This fact is not unanimous. Some women, particularly those troubled by swelling and 
weight gain, made a clear relation between the hormonal composition of oral and non-oral 
steroid contraceptives. 
10. In Brazil, most implant users obtain these through private gynecologists who source them 
via compounding pharmacies. Hormonal implants are presented as individually tailored to a 
patient’s hormonal profile. For details on compounding pharmacies, see Sanabria (2010b).  
11. For a detailed ethnographic analysis of the operation of pharmacies in India, where most 
drugs are also available over the counter, see Kamat and Nichter 1998.  
12. For an important critique of the routine use of the term “self-medication” see Das and Das 
(2006). 
13. This is an example of what Oldani (2004) refers to as a “novel [pharmaceutical] gift 
cycle.” 
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14. This margin may be significant for active principles that have narrow therapeutic indexes, 
such as ARVs or hormonal contraceptives. For these drugs, minute variations that remain 
within the margin allowed by bioequivalence testing may have significant clinical effects 
(Rumel et al. 2006).  
15. According to the Federal Council of Pharmacy, 18,000 drug prescriptions exist in Brazil, 
70% of which are similares, the remaining 30% being either brand-name or generic drugs. 
See http://www.cff.org.br/sistemas/geral/revista/pdf/78/10-anvisa.pdf (accessed March 21, 
2013). 
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